February 22, 2024

Rasi Bhadramani/iStock by way of Getty Pictures

Sagimet Biosciences Inc. (NASDAQ:SGMT) simply reported constructive outcomes from its section 2b examine utilizing denifanstat for the remedy of sufferers with F2-F3 non-alcoholic steatohepatitis [NASH]. It was in a position to meet each main